GoAI
Get started
XBiotech Inc. logo

XBiotech Inc.

XBIT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$2.28

−$0.03 · -1.30%

Aug 21, 4:00 PM ET

XBIT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

57

Fair Value

Momentum

41

Neutral

Sentiment

56

Mixed

Risk resilience

54

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Sushma Shivaswamy
Listed since
Apr 15, 2015
Employees
87

Market position

Day range

Current $2.28

52-week range

Current $2.28

Open
$2.29
Previous close
$2.31
Volume
11.02K
0.35× average
Average volume
31.09K
Average daily volume
Market cap
69.51M USD
Beta
0.85
Market reference 1
50-day average
$2.3029
-0.99% below average
200-day average
$2.3976
-4.91% below average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
6.39
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends178%-199%-577%-954%Gross margin, FY2021: 68.36%Gross margin, FY2022: 83.77%Operating margin, FY2021: -136.36%Operating margin, FY2022: -860.10%Net margin, FY2021: -94.67%Net margin, FY2022: -820.45%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.36%. Gross margin FY2022 83.77%. Operating margin FY2021 -136.36%. Operating margin FY2022 -860.10%. Net margin FY2021 -94.67%. Net margin FY2022 -820.45%.

Income trends

Revenue

4.01M USD-78.20%

Operating income

−55.69M USD-31.11%

Net income

−45.54M USD-18.19%
Income trends across reported periods25.8M USD−3.83M USD−33.46M USD−63.09M USDRevenue, FY2021: 18.39M USDRevenue, FY2022: 4.01M USDOperating income, FY2021: −25.08M USDOperating income, FY2022: −34.49M USDOperating income, FY2023: −37.51M USDOperating income, FY2024: −42.47M USDOperating income, FY2025: −55.69M USDNet income, FY2021: −17.41M USDNet income, FY2022: −32.9M USDNet income, FY2023: −24.56M USDNet income, FY2024: −38.53M USDNet income, FY2025: −45.54M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 18.39M USD. Revenue FY2022 4.01M USD. Operating income FY2021 −25.08M USD. Operating income FY2022 −34.49M USD. Operating income FY2023 −37.51M USD. Operating income FY2024 −42.47M USD. Operating income FY2025 −55.69M USD. Net income FY2021 −17.41M USD. Net income FY2022 −32.9M USD. Net income FY2023 −24.56M USD. Net income FY2024 −38.53M USD. Net income FY2025 −45.54M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue———4.01M USD18.39M USD
Cost of goods sold1.69M USD——651K USD5.82M USD
Gross profit−1.69M USD——3.36M USD12.57M USD
Research and development47.39M USD37.76M USD32.85M USD31.54M USD28.27M USD
Selling, general, and administrative8.3M USD4.71M USD4.66M USD6.31M USD9.39M USD
Operating expenses54M USD42.47M USD37.51M USD37.85M USD37.66M USD
Interest income5.68M USD9.81M USD10.42M USD3.82M USD467K USD
Interest expense88K USD807K USD———
Depreciation and amortization1.69M USD1.75M USD1.74M USD2.61M USD2.65M USD
Operating income−55.69M USD−42.47M USD−37.51M USD−34.49M USD−25.08M USD
Net income−45.54M USD−38.53M USD−24.56M USD−32.9M USD−17.41M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
0%
0 beats, 3 misses, 0 met estimates
Average EPS surprise
-1277.78%
3 comparable reports
Latest EPS result
-0.22
Estimate 0.03 · Miss by 833.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.11-0.24-0.6-0.95Q4 '24No estimateQ1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26MissQ2 '26MissQ3 '26Miss
Q4 2024, reported Nov 13, 2024: actual -0.16, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 18, 2025: actual -0.34, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual -0.36, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 13, 2025: actual -0.06, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 12, 2025: actual -0.2, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 13, 2026: actual -0.88, estimate 0.04, surprise -2300.00%, Miss. Q2 2026, reported May 14, 2026: actual -0.18, estimate 0.03, surprise -700.00%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.22, estimate 0.03, surprise -833.33%, Miss.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates7.35M5.66M3.96M2.27MQ4 '23EstimateQ1 '24MissQ2 '24EstimateQ3 '24EstimateQ1 '26EstimateQ2 '26EstimateQ3 '26Estimate
Q4 2023, reported Nov 9, 2023: actual —, estimate 7M USD, surprise —, Comparison unavailable. Q1 2024, reported Mar 15, 2024: actual 2.62M USD, estimate 7M USD, surprise -62.57%, Miss. Q2 2024, reported May 10, 2024: actual —, estimate 7M USD, surprise —, Comparison unavailable. Q3 2024, reported Aug 12, 2024: actual —, estimate 7M USD, surprise —, Comparison unavailable. Q1 2026, reported Mar 13, 2026: actual —, estimate 7M USD, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual —, estimate 7M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 13, 2026: actual —, estimate 7M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

XBIT news

Corporate actions

Corporate action history

Dividend

Ex-dividend Jul 15, 2021

$2.50

Special

Record Jul 16, 2021 · Payment Jul 23, 2021

XBIT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding XBIT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
446.41K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
183.93K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
EA Bridgeway Omni Small-Cap Value ETF logoEA Bridgeway Omni Small-Cap Value ETFBSVO
Market value
140K
Weight
0.01%
AUM
1.71B USD
Expense ratio
0.47%
Price / 1D
$29.62+0.85%
Avantis U.S. Small Cap Equity ETF logoAvantis U.S. Small Cap Equity ETFAVSC
Market value
30.56K
Weight
—
AUM
3.16B USD
Expense ratio
0.25%
Price / 1D
$73.84+0.70%

Continue in GoAI

Research XBIT

research.disclaimer